Finance

Vitex Reports Third Quarter 2001 Results

Published in Blood Weekly, December 6th, 2001

V.I. Technologies, Inc., (VITX), a biotechnology company that develops products that inactivate and remove pathogens in blood, has announced its financial results for the third quarter ended September 30, 2001.

For the third quarter of 2001, Vitex reported a net loss of $2.7 million, or $0.12 per share, compared with a net loss of $5.0 million or $0.25 per share, for the third quarter of 2000. Net revenues for the third quarter of 2001 were $5.2 million compared with $9.4 million for the third quarter of 2000.

On August 14, 2001, Vitex completed the divestiture of its plasma operations to Precision Pharma Services. The plasma operations accounted...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-12-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry